CoChat

A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

Open access
Qiu, Zhengang, Lin, Anqi, Li, Kun, Lin, Weiyin, Wang, Qiongyao, Wei, Ting, Zhu, Weiliang, Luo, Peng, Zhang, Jian · 2019 · Drug Design, Development and Therapy
Cited by 74

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Platinum-based chemotherapy, consisting of etoposide and cisplatin (EP), has been the cornerstone of therapy for extensive-stage small-cell lung cancer (ES-SCLC) for decades. Despite the marked initial sensitivity of SCLC to chemotherapy, EP regimens cannot avoid the emergence of drug resistance in clinical practice. With the rise of new chemotherapy regimens in recent years and the primary resistance or insensitivity of ES-SCLC to EP regimens, it is desirable to be able to identify patients with resistant or insensitive ES-SCLC. Methods: The sequencing and drug sensitivity data of SCLC cell lines were provided by The Genomics of Drug Sensitivity in Cancer Project (GDSC). The data regarding sensitivity to etoposide of 54 SCLC cell lines were analyzed, and etoposide-sensitive cell lines and etoposide-resistant cell lines were differentiated according to the IC50 values defined by the GDSC. ROC curve analysis was performed on all mutations and combinations of mutations to select the optimal panel to predict resistance to etoposide. Results: ROC analysis of etoposide resistance revealed that the most significant single gene mutation indicating resistance to etoposide was CSMD3 , and the accuracy of predicting resistance to etoposide proved to be the highest when there was any mutation in CSMD3/PCLO/RYR1/EPB41L3 , area under the curve =0.804 (95% confidence interval: 0.679–0.930, P <0.001 ). Conclusion: This study found that a panel with four genes ( CSMD3, EPB41L3, PCLO, and RYR1 ) can accurately predict sensitivity to etoposide. These findings provide new insights into the overall treatment for patients with ES-SCLC that is resistant or insensitive to etoposide. Keywords: small-cell lung carcinoma, etoposide, EP regimens, IP regimens, gene mutation

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s205633

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 74

Metadata

Authors
Qiu, Z., Lin, A., Li, K., Lin, W., Wang, Q., Wei, T., Zhu, W., Luo, P., & Zhang, J.
Venue
Drug Design, Development and Therapy
Published
2019-06
Volume
Volume 13
Pages
2021-2041
ISSN
1177-8881 (ISSN-L)
OpenAlex
W2949487479
Cited by
74
References
5
FWCI
5.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel mutation panel for predicting etoposide resistance in small-cell lung cancer. https://app.cochat.ai/papers/10.2147/dddt.s205633
The paper
Qiu, Z., Lin, A., Li, K., Lin, W., Wang, Q., Wei, T., Zhu, W., Luo, P., & Zhang, J. (2019). A novel mutation panel for predicting etoposide resistance in small-cell lung cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s205633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.